Epinecidin-8
General Information
DCTPep ID DCTPep00454
Peptide Name Epinecidin-8
Sequence FIFHIIKGLFHAGKMI
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin Epinephelus nebulosus
Type Native peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | ~70% Cytotoxicity=25 mg/L | MTS assay | 6 h | 1 |
HT-1080 | Fibrosarcoma | ~85% Cytotoxicity=25 mg/L | MTS assay | 6 h | 1 |
Hemolytic Activity EP-8 did not have a strong hemolytic effect at low doses
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00454
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C93H142N22O17S1
Absent amino acids CDENPQRSTVWY
Theoretical pI 10.00
Acidic residues 0
Basic residues 4
Polar residues 2
Molecular weight (Average) 1872.35
Molecular weight (Monoisotopic) 1871.06
Common amino acids I
Net charge 4
Instability index (II) 41.29
Aliphatic index 128.12
Grand average of hydropathicity (GRAVY) 1.181
Half Life
1.1 hours (mammalian reticulocytes, in vitro).
3 min (yeast, in vivo).
2 min (Escherichia coli, in vivo).
Extinction coefficients
Should not be visible by UV spectrophotometry.
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 23598079
Title Truncated antimicrobial peptides from marine organisms retain anticancer activity and antibacterial activity against multidrug-resistant Staphylococcus aureus
Doi 10.1016/j.peptides.2013.04.004
Year 2013
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available